<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01074567</url>
  </required_header>
  <id_info>
    <org_study_id>174/09</org_study_id>
    <nct_id>NCT01074567</nct_id>
  </id_info>
  <brief_title>DMSO Efficacy in IC/PBS Patients During and After Treatment</brief_title>
  <official_title>Efficacy of DMSO Cocktail Treatment in Interstitial Cystitis Patients During and After Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assaf-Harofeh Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assaf-Harofeh Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to examine the efficacy of dimethylsulphoxide (DMSO) cocktail in
      patients with interstitial cystitis during the treatment period (12 weeks) and after it (at 6
      weeks, 3, 6 and 12 month).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The modern treatment of IC is a multi-modal treatment which includes behavioural treatment,
      physiotherapy of the pelvic floor musculature, oral medication (e.g. Amitryptiline) and
      intra-vesical instillation (e.g. DMSO, steroids, heparin). These treatments were found to be
      effective in a number of studies and are approved by the FDA. However, the optimal duration
      of intra-vesical instilation is not known.

      All patients with IC (according to the international continence society criteria) will
      receive 12 weekly intra-vesical instillation of DMSO. All patients will fill an O'leary-Sant
      questionaire and a urination diary before treatment, after 3, 6, 9 and 12 treatments and at 6
      weeks, 3, 6 and 12 month after the end to the treatment.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2009</start_date>
  <completion_date type="Anticipated">December 2012</completion_date>
  <primary_completion_date type="Anticipated">December 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>O'leary-Sant interstitial cystitis symptom and problem questionaire</measure>
    <time_frame>before treatment, at 3, 6, 9 and 12 treatments, 6 weeks, 3, 6, 12 month after last treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>urination diary</measure>
    <time_frame>before treatment, at 3, 6, 9 and 12 treatments, 6 weeks, 3, 6, 12 month after last treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Cystitis, Interstitial</condition>
  <arm_group>
    <arm_group_label>DMSO cocktail</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>intra-vesical: DMSO 50% in 50 cc water for injection 10 cc heparin 5000 IU hydrocortisone 100 mg bupivacaine 0.125%</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DMSO cocktail</intervention_name>
    <description>intra-vesical: DMSO 50% in 50 cc water for injection 10 cc heparin 5000 IU hydrocortisone 100 mg bupivacaine 0.125%</description>
    <arm_group_label>DMSO cocktail</arm_group_label>
    <other_name>Dimethyl sulfoxide</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients with IC according to International Continence Society:

               -  more than 6 month of pelvic pain

               -  urinary frequency, urgency, dyspareunia

        Exclusion Criteria:

          -  genitourinary tract infection

          -  known genitourinary malformation
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kobi Stav, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assaf-Harofe MC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kobi Stav, MD</last_name>
    <phone>+972-8-9779400</phone>
    <email>stavkobi@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Miki Haifler, MD</last_name>
    <phone>+972-8-9401</phone>
    <email>mikihaifler@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Assaf Harofe Medical Center</name>
      <address>
        <city>Zeriffin</city>
        <zip>70300</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kobi Stav, MD</last_name>
      <phone>+972-577346778</phone>
      <email>stavkobi@yahoo.com.au</email>
    </contact>
    <contact_backup>
      <last_name>Miki Haifler, MD</last_name>
      <phone>+972-523271255</phone>
      <email>mikihaifler@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <link>
    <url>http://www.painful-bladder.org/index.html</url>
    <description>international painful bladder foundation</description>
  </link>
  <link>
    <url>http://www.ichelp.org</url>
    <description>interstitial cystitis association</description>
  </link>
  <verification_date>March 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 23, 2010</study_first_submitted>
  <study_first_submitted_qc>February 23, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 24, 2010</study_first_posted>
  <last_update_submitted>April 4, 2011</last_update_submitted>
  <last_update_submitted_qc>April 4, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 5, 2011</last_update_posted>
  <responsible_party>
    <name_title>Miki Haifler</name_title>
    <organization>Assaf-Harofeh Medical Center</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cystitis</mesh_term>
    <mesh_term>Cystitis, Interstitial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dimethyl Sulfoxide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

